Nanotechnology Stocks To Follow Now – May 28th

OSI Systems, NVE, Biodexa Pharmaceuticals, Clene, Virpax Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are shares of publicly traded companies whose core businesses involve researching, developing or manufacturing materials and devices engineered at the nanoscale (one billionth of a meter). By investing in these equities, shareholders gain exposure to potential breakthroughs in fields like electronics, medicine, energy and advanced materials. Because nanotech often requires long development cycles and faces technical or regulatory hurdles, these stocks can exhibit higher risk and price volatility than more established technology sectors. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

OSIS stock traded down $9.74 during midday trading on Wednesday, hitting $217.99. The company’s stock had a trading volume of 168,828 shares, compared to its average volume of 193,166. The company’s fifty day moving average price is $205.32 and its 200 day moving average price is $190.03. OSI Systems has a twelve month low of $129.18 and a twelve month high of $234.59. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. The stock has a market capitalization of $3.66 billion, a P/E ratio of 28.06, a PEG ratio of 1.81 and a beta of 1.28.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

NVE stock traded down $0.41 during trading hours on Wednesday, hitting $73.89. The company had a trading volume of 11,345 shares, compared to its average volume of 22,823. The firm has a market cap of $357.38 million, a PE ratio of 23.83 and a beta of 1.09. NVE has a one year low of $51.50 and a one year high of $89.98. The firm has a 50-day moving average of $63.05 and a 200 day moving average of $71.01.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of NASDAQ BDRX traded down $0.08 during trading hours on Wednesday, hitting $1.07. 441,664 shares of the stock were exchanged, compared to its average volume of 837,608. Biodexa Pharmaceuticals has a 1-year low of $1.04 and a 1-year high of $41.50. The company’s fifty day simple moving average is $1.43 and its two-hundred day simple moving average is $3.17.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

CLNN remained flat at $2.62 during midday trading on Wednesday. The company’s stock had a trading volume of 61,250 shares, compared to its average volume of 81,814. The company has a market cap of $23.54 million, a P/E ratio of -0.50 and a beta of 0.46. Clene has a 1 year low of $2.28 and a 1 year high of $9.20. The stock has a 50 day moving average of $2.91 and a two-hundred day moving average of $4.04.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

NASDAQ:VRPX traded up $0.05 during trading hours on Wednesday, hitting $0.29. The stock had a trading volume of 5,605 shares, compared to its average volume of 201,323. The company has a 50 day simple moving average of $0.49 and a two-hundred day simple moving average of $5.75. Virpax Pharmaceuticals has a one year low of $0.13 and a one year high of $84.75.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Shares of NASDAQ CLNNW traded up $0.00 during mid-day trading on Wednesday, reaching $0.03. 100 shares of the company were exchanged, compared to its average volume of 10,882. The company’s 50 day moving average price is $0.03 and its 200 day moving average price is $0.04. Clene has a 52 week low of $0.02 and a 52 week high of $0.08.